These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 30281547

  • 1. Antibiotic Resistance Among Pediatric-Sourced Ocular Pathogens: 8-Year Findings From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.
    Alter SJ, Sanfilippo CM, Asbell PA, DeCory HH.
    Pediatr Infect Dis J; 2019 Feb; 38(2):138-145. PubMed ID: 30281547
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018.
    Asbell PA, Sanfilippo CM, Sahm DF, DeCory HH.
    JAMA Ophthalmol; 2020 May 01; 138(5):439-450. PubMed ID: 32271355
    [Abstract] [Full Text] [Related]

  • 4. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study.
    Haas W, Pillar CM, Torres M, Morris TW, Sahm DF.
    Am J Ophthalmol; 2011 Oct 01; 152(4):567-574.e3. PubMed ID: 21652021
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009-2016).
    Thomas RK, Melton R, Asbell PA.
    Clin Optom (Auckl); 2019 Oct 01; 11():15-26. PubMed ID: 30881168
    [Abstract] [Full Text] [Related]

  • 7. Antibiotic resistance of bacterial pathogens isolated from the conjunctiva in the Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study (2009-2021).
    Asbell PA, Sanfilippo CM, DeCory HH.
    Diagn Microbiol Infect Dis; 2024 Jan 01; 108(1):116069. PubMed ID: 37918187
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R, Noriega ER, Dowzicky MJ.
    Ann Clin Microbiol Antimicrob; 2015 Dec 15; 14():53. PubMed ID: 26667651
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Surveillance of the Activity of Aminoglycosides and Fluoroquinolones Against Ophthalmic Pathogens from Europe in 2010-2011.
    Sanfilippo CM, Morrissey I, Janes R, Morris TW.
    Curr Eye Res; 2016 May 15; 41(5):581-9. PubMed ID: 26200173
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M, Browne FA, Jacobs MR, Appelbaum PC.
    Clin Ther; 2003 Jan 15; 25(1):169-77. PubMed ID: 12637118
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.